Inside Eli Lilly’s Strategic Investment In Sigilon: An Opportunity Overlooked

Indianapolis - April 2016: Eli Lilly and Company V


Pharma giant Eli Lilly and Company (NYSE:LLY) is buying the tiny biotech Sigilon Therapeutics, Inc. (NASDAQ:SGTX) for $14.92 per share in cash. The shares are trading at $21.28 due to a contingent value right ((

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *